Search
Now showing items 1-8 of 8
Acetylation increases access of remodelling complexes to their nucleosome targets to enhance initiation of V(D)J recombination.
(2007-01)
Targeted chromatin remodelling is essential for many nuclear processes, including the regulation of V(D)J recombination. ATP-dependent nucleosome remodelling complexes are important players in this process whose activity ...
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential
(COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, 2007-11-01)
Oncogenic mutations of the MLL histone methyltransferase confer an unusual ability to transform non-self-renewing myeloid progenitors into leukemia stem cells (LSCs) by mechanisms that remain poorly defined. Misregulation ...
Combinatorial effects of splice variants modulate function of Aiolos
(2007)
The transcription factor Aiolos ( also known as IKZF3), a member of the Ikaros family of zinc-finger proteins, plays an important role in the control of B lymphocyte differentiation and proliferation. Previously, multiple ...
Short-term presurgical treatment for all?
(BIOMED CENTRAL LTD, 2007-01-01)
Calculation of x-ray spectra emerging from an x-ray tube. Part I. electron penetration characteristics in x-ray targets.
(WILEY, 2007-06-01)
The penetration characteristics of electron beams into x-ray targets are investigated for incident electron kinetic energies in the range 50-150 keV. The frequency densities of electrons penetrating to a depth x in a target, ...
Stringent and reproducible tetracycline-regulated transgene expression by site-specific insertion at chromosomal loci with pre-characterised induction characteristics
(2007-01-01)
Background: The ability to regulate transgene expression has many applications, mostly concerning the analysis of gene function. Desirable induction characteristics, such as low un-induced expression, high induced expression ...
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.
(NATURE PUBLISHING GROUP, 2007-01-15)
Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter clinical trial. Preclinical studies showed antitumour activity in a broad range ...